Form 4: ENDRA Life Sciences Director Anthony DiGiandomenico Granted Restricted Stock Units

ENDRA Life Sciences Inc. Director Anthony DiGiandomenico was granted 5,384 restricted stock units, which are scheduled to vest in full on June 11, 2026.

Summary

• Anthony DiGiandomenico, a Director of ENDRA Life Sciences Inc. (NDRA), acquired 5,384 shares of common stock in the form of restricted stock units (RSUs).
• The transaction date for this acquisition was June 11, 2025.
• These RSUs convert to common stock on a one-for-one basis and were acquired at a price of $0 per unit.
• The entire grant of 5,384 RSUs is scheduled to vest in full on June 11, 2026.
• Following this transaction, Anthony DiGiandomenico beneficially owns a total of 5,443 shares of common stock directly.

Sentiment

Score: 6

Explanation: The grant of RSUs to a director is a positive sign of alignment and retention, though it's a routine compensation event rather than a significant operational or financial development.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The acquisition of additional equity by a director demonstrates continued commitment to the company.

Future Outlook

The vesting schedule for the restricted stock units indicates a future milestone for the director's equity compensation, aligning with long-term retention strategies.

Industry Context

This transaction is a standard form of equity compensation for directors in the life sciences industry, aiming to retain talent and align interests with company performance.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacting all employees, it reflects standard compensation practices for leadership, which can influence overall compensation philosophy.

Next Steps

• The 5,384 restricted stock units are scheduled to vest in full on June 11, 2026, at which point they will convert to common stock.

Key Dates

Keywords

ENDRA Life Sciences, NDRA, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, director compensation, equity grant, Anthony DiGiandomenico